The short version of Dipeptidyl peptidase-4 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-17 and is reviewed periodically as new material appears.
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| 外观 | 白色至类白色冻干粉 | 可能具吸湿性 |
| 溶解性 | 溶于水和水性缓冲液 | 典型肽类行为 |
| 冻干粉储存 | -20°C 或 2-8°C，避光 | 长期稳定性较好 |
| 复溶后储存 | 2-8°C，短期 | 避免反复冻融 |
| 常用分析 | RP-HPLC 与 LC-MS | 纯度与身份确认 |
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
==== Azetidine based compounds ==== Informations for this group of inhibitors are quite restricted. Azetidine-based DPP-4 inhibitors can roughly be grouped into three main subcategories: 2-cyanoazetidines, 3-fluoroazetidines, and 2-ketoazetidines. The most potent ketoazetidines and cyanoazetidines have large hydrophobic amino acid groups bound to the azetidine nitrogen and are active below 100nM.
== External links == Media related to Protons at Wikimedia Commons Particle Data Group at LBL Large Hadron Collider Eaves, Laurence; Copeland, Ed; Padilla, Antonio (Tony) (2010). "The shrinking proton". Sixty Symbols. Brady Haran for the University of Nottingham. MIT proton visualization project: Inside the Proton, the 'Most Complicated Thing You Could Possibly Imagine', Quanta Magazine, Oct 19 2022 Visualizing the Proton, Arts at MIT, 2022
Researchers reported numerous "chemical strains" or chemotypes: lichens identical in appearance yet separable by their metabolites. For instance, MacKenzie (1951) noted that morphologically identical Stereocaulon tomentosum forms differed in chemistry—one containing stictic acid, the other fumarprotocetraric acid. These chemotypes often occupy different regions or microhabitats, and breeding or DNA data have since supported treating them as separate species. Metabolite profiles also informed higher-level classification. In some cases, entire genera were defined or redefined by their chemical profiles. In the Cetraria group, species rich in specific fatty acids were placed in Platismatia, whereas taxa containing orcinol depsidones were transferred to Cetrelia; the shift was consistent with their chemical differences. Chemical data further resolved misclassifications based solely on morphology. For example, species formerly combined in Anaptychia were divided after researchers noted that forms with thick-walled spores and a medulla containing zeorin plus specific depsidones formed a coherent group (Heterodermia), whereas thin-walled, chemically simpler taxa stayed in Anaptychia.
Sources: en.wikipedia.org
=== Pancreatitis and pancreatic cancer === An association of the DPP-IV inhibitor class with pancreatic problems has been proposed, mainly based on case reports associated with the DPP-IV inhibitor sitagliptin and several incretin mimetics including exenatide. A 2013 study of the DPP-4 inhibitor sitagliptin reported found "worrisome changes in the pancreases of the rats that could lead to pancreatic cancer". A second paper by the same authors reported an increase in precancerous lesions in the pancreases of organ donors who had taken GLP-1 inhibitors. In response to these reports, the United States FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-IV inhibitors with pancreatic cancer. In a joint letter to the New England Journal of Medicines, the agencies stated that "Both agencies agree that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data. The FDA and the EMA have not reached a final conclusion at this time regarding such a causal relationship.
== External links == Glutamate+Aspartate+Transporter+1 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P43003 (Excitatory amino acid transporter 1) at the PDBe-KB.
=== Bibliography === Aerei da combattimento della Seconda Guerra Mondiale (in Italian). Novara, Italy: De Agostini Editore, 2005. Anderson, Peter N. Mustangs of the RAAF and RNZAF. Sydney, Australia: A.H. & A.W. Reed Pty Ltd, 1975. ISBN 0-589-07130-0. Angelucci, Enzo and Peter Bowers. The American Fighter: The Definitive Guide to American Fighter Aircraft from 1917 to the Present. New York: Orion Books, 1985. ISBN 0-517-56588-9. Aro, Chuck and Colin Aro. "World's Fastest Mustangs". Air Enthusiast. No. 13, August–November 1980. pp. 56–62. ISSN 0143-5450 Birch, David. Rolls-Royce and the Mustang. Derby, UK: Rolls-Royce Heritage Trust, 1987. ISBN 0-9511710-0-3. Bowen, Ezra. Knights of the Air (Epic of Flight). New York: Time-Life Books, 1980. ISBN 0-8094-3252-8. Borth, Christy. Masters of Mass Production. Indianapolis, Indiana: Bobbs-Merrill Co., 1945. Bowman, Martin W. P-51 Mustang vs Fw 190: Europe 1943–45. Oxford, UK: Osprey Publishing, 2007. ISBN 1-84603-189-3. Boylan, Bernard. Development of the Long Range Escort Fighter. Washington, D.C.: USAF Historical Division, Research Studies Institute, Air University, 1955. Retrieved: 15 July 2014. Boyne, Walter J. Clash of Wings. New York: Simon & Schuster, 1994. ISBN 0-684-83915-6. Breffort, Dominique with André Jouineau. Le North-American P-51 Mustang – de 1940 à 1980 (Avions et Pilotes 5)(in French). Paris: Histoire et Collections, 2003. ISBN 2-913903-80-0. Bridgman, Leonard, ed. "The North American Mustang." Jane's Fighting Aircraft of World War II. London: Studio, 1946. ISBN 1-85170-493-0.
The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommended the use of ramelteon in the treatment of sleep-onset insomnia. It rated the recommendation as weak and the quality of evidence as very low but concluded that the potential benefits outweighed the potential harms. The guidelines found that ramelteon reduces sleep latency by 9 minutes (95% CITooltip confidence interval 6–12 minutes) but does not improve sleep quality. In contrast to ramelteon, the guidelines did not recommend the use of melatonin.
Sources: en.wikipedia.org
The NADH formed in the third oxidative step cannot be reoxidized in the peroxisome, so reducing equivalents are exported to the cytosol. β-oxidation in the peroxisome requires the use of a peroxisomal carnitine acyltransferase (instead of carnitine acyltransferase I and II used by the mitochondria) for transport of the activated acyl group into the mitochondria for further breakdown. The first oxidation step in the peroxisome is catalyzed by the enzyme acyl-CoA oxidase. The β-ketothiolase used in peroxisomal β-oxidation has an altered substrate specificity, different from the mitochondrial β-ketothiolase. Peroxisomal oxidation is induced by a high-fat diet and administration of hypolipidemic drugs like clofibrate.
The new 27th district stretches across the Coastal Bend, from downtown Corpus Christi and Port Aransas in the south, along with Victoria and the rural fringes of the Greater Houston area including Brenham, Bay City and Sealy, extending westward to La Grange along with the southern and eastern suburbs of Austin including Bastrop, Kyle and Lockhart along with an eastern sliver of Travis County (including the Circuit of the Americas). The incumbent is Republican Michael Cloud, who was re-elected with 66.0% of the vote in 2024. A plurality White district whose voting age population is more than 40% Hispanic, Donald Trump won 60% of the vote and Ted Cruz 57.1% in 2024.
In Ancient Greece, the Hippocratic Corpus described the anatomy of the skeleton and muscles. The 2nd century physician Galen of Pergamum compiled classical knowledge of anatomy into a text that was used throughout the Middle Ages. In the Renaissance, Andreas Vesalius (1514–1564) pioneered the modern study of human anatomy by dissection, writing the influential book De humani corporis fabrica. Anatomy advanced further with the invention of the microscope and the study of the cellular structure of tissues and organs. Modern anatomy uses techniques such as magnetic resonance imaging, computed tomography, fluoroscopy and ultrasound imaging to study the body in unprecedented detail.
== Vasoactive Intestinal Peptide (VIP) and SARS-CoV-2 == VIP is highly localised in lungs and binds with alveolar type II (AT II) cells via VPAC1 receptor. AT II cells constitute only 5% of pulmonary epithelium. Angiotensin Converting Enzyme 2 (ACE 2) surface receptors are present in AT II cells. AT II cells produces surfactant and plays an important role in the maintenance of type 1 epithelial cells. SARS-CoV-2 enters into AT II cells by binding to ACE 2 surface receptors with its spike protein.
In rodent drug discrimination studies, muscimol and gaboxadol fully generalize between each other, but generalization between benzodiazepines like diazepam does not occur. These findings suggest that muscimol and gaboxadol have differing interoceptive effects from those of benzodiazepines. During a test involving rabbits connected to an EEG, muscimol presented with a distinctly synchronized EEG tracing. This is substantially different from serotonergic psychedelics like psilocybin, with which brainwave patterns generally show a desynchronization. In higher doses (2 mg/kg via IV), the EEG will show characteristic spikes. Muscimol can increase prolactin and growth hormone levels in humans.
Sources: en.wikipedia.org
反相高效液相色谱用于分离和纯度评估，质谱用于分子量确认。肽图谱或串联质谱可进一步验证序列。具体方法需根据样品基质和监管要求选择。
高温、强光、潮湿和反复冻融都会加速肽降解。冻干粉通常建议低温避光保存。复溶后的溶液稳定性较短，应依据验证数据确定保存条件。
氧化、脱酰胺和截短肽可能影响色谱纯度和生物活性读数。不同批次之间这些杂质的相对比例可能不同。是否具有临床意义取决于杂质水平、给药途径和暴露量，尚无统一阈值。
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.